UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil

Cancers, 2024-09, Vol.16 (17), p.3063

2024

Volltextzugriff (PDF)

MM-722 Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide Thalidomide, Dexamethasone, and Daratumumab

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S580-S580

2024

Volltextzugriff (PDF)

Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide, Thalidomide, Dexamethasone, and Daratumumab

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S246-S246

2024

Volltextzugriff (PDF)

Current Practices on Therapy of Acute Graft Versus Host Disease (aGVHD) in Latin America (LA): Interim Results of a WBMT Survey

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S330-S330

2024

Volltextzugriff (PDF)

Current Practices on Prophylaxis of Graft Versus Host Disease (GVHD) in Latin America (LA): Interim Results of a WBMT Survey

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S334-S334

2024

Volltextzugriff (PDF)

Comparative Outcomes for HLA-Matched Siblings, Mismatched, and Haploidentical Donors in Myelodisplastic Syndromes: Report from the Latin American Register

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S304-S304

2024

Volltextzugriff (PDF)

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

Oncotarget, 2023-12, Vol.14 (1), p.977-994

2023

Volltextzugriff (PDF)

10-year real-world data on acute myeloid leukemia: The paradigm of a public health center in Brazil

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19022-e19022

2023

Volltextzugriff (PDF)

403 - In the Molecular Classification Era, Can We Still Use IPSS-R in HSCT of MDS Patients?

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S304-S305

2023

Volltextzugriff (PDF)

In the Molecular Classification Era, Can We Still Use IPSS-R in HSCT of MDS Patients?

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S304-S305

2023

Volltextzugriff (PDF)

Retrospective Observational Study of the Long-Term Safety and Efficacy Outcomes of Rituximab Biosimilar: Partial Data of RTXM83-AC-01-11 Subanalysis Study

Blood, 2022-11, Vol.140 (Supplement 1), p.13236-13238

2022

Volltextzugriff (PDF)

Variability in End-of-Life Care and Perception of Palliative Care Among Physicians in the Hematology Unit of a Reference Service in the State of Bahia, Brazil

Blood, 2022-11, Vol.140 (Supplement 1), p.13295-13296

2022

Volltextzugriff (PDF)

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Blood, 2022-11, Vol.140 (Supplement 1), p.7699-7700

2022

Volltextzugriff (PDF)

Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.10000-10000

2022

Volltextzugriff (PDF)

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.4927-4927

2021

Volltextzugriff (PDF)

Difference in FLT3 Mutational Status between Diagnosis and Relapsed/Refractory Acute Myeloid Leukemia: A Meta-Analysis

Blood, 2020-11, Vol.136 (Supplement 1), p.28-29

2020

Volltextzugriff (PDF)

10-Year Real-World Data on Acute Myeloid Leukemia: The Paradigm of a Public Health Center in Brazil

Blood, 2020-11, Vol.136 (Supplement 1), p.33-34

2020

Volltextzugriff (PDF)

Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

Blood, 2020-11, Vol.136 (Supplement 1), p.3-4

2020

Volltextzugriff (PDF)

Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.17-18

2020

Volltextzugriff (PDF)

Influence of the Cell Source and Conditioning System on Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Biology of blood and marrow transplantation, 2020-03, Vol.26 (3), p.S299-S300

2020

Volltextzugriff (PDF)

Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e145-e146

2019

Volltextzugriff (PDF)

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

Blood, 2018-11, Vol.132 (Supplement 1), p.2161-2161

2018

Volltextzugriff (PDF)

Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study

Medical oncology (Northwood, London, England), 2018-11, Vol.35 (11), p.141-6, Article 141

2018

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(48)
Berichte
(1)

Sprache

Englisch
(46)
Portugiesisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil

MM-722 Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide Thalidomide, Dexamethasone, and Daratumumab

Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide, Thalidomide, Dexamethasone, and Daratumumab

Current Practices on Therapy of Acute Graft Versus Host Disease (aGVHD) in Latin America (LA): Interim Results of a WBMT Survey

Current Practices on Prophylaxis of Graft Versus Host Disease (GVHD) in Latin America (LA): Interim Results of a WBMT Survey

Comparative Outcomes for HLA-Matched Siblings, Mismatched, and Haploidentical Donors in Myelodisplastic Syndromes: Report from the Latin American Register

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

10-year real-world data on acute myeloid leukemia: The paradigm of a public health center in Brazil

403 - In the Molecular Classification Era, Can We Still Use IPSS-R in HSCT of MDS Patients?

In the Molecular Classification Era, Can We Still Use IPSS-R in HSCT of MDS Patients?

Retrospective Observational Study of the Long-Term Safety and Efficacy Outcomes of Rituximab Biosimilar: Partial Data of RTXM83-AC-01-11 Subanalysis Study

Variability in End-of-Life Care and Perception of Palliative Care Among Physicians in the Hematology Unit of a Reference Service in the State of Bahia, Brazil

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL)

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Difference in FLT3 Mutational Status between Diagnosis and Relapsed/Refractory Acute Myeloid Leukemia: A Meta-Analysis

First Description of Upfront Target Therapy Treating AML and Bcll Presented Simultaneously As First Line

10-Year Real-World Data on Acute Myeloid Leukemia: The Paradigm of a Public Health Center in Brazil

Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Influence of the Cell Source and Conditioning System on Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study

Aktive Filter

Suchergebnisse filtern